September 30, 2026, 10:01 to October 7, 2026, 10:01 (JST)This week, progress was made in preparing for U.S. regulatory ...

Adding aglatimagene besadenovec (CAN-2409) to external beam radiation therapy (EBRT) was associated with greater lymphocyte infiltration of prostate tissue and greater lymphocyte- ...

A new theranostics suite is streamlining treatment and clinical trials for certain types of cancer, notably prostate cancer ...

For men diagnosed with localized prostate cancer, radiation treatment has long meant a difficult trade-off: either endure ...

Intensity-modulated proton therapy (IMPT) allows radiation oncologists to limit the dose to organs surrounding the prostate. That property may be particularly relevant for patients with prostate ...

The pre-formed and radiopaque flex hydrogel spacer is now FDA approved and will begin limited distribution in the US. The US Food and Drug Administration (FDA) has granted 510 (k) clearance for ...

Radiation therapy starts damaging cancer cells during treatment, but most cells do not die immediately. Radiation works ...

IBA to offer QUANTM Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium - October 1st, 2026, 7 ...

Candel Therapeutics, Inc. announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial (NCT07332000) in patients with intermediate-risk localized prostate cancer. These data, ...

Candel Therapeutics, Inc. announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- ...

Opinion: One in 44 men will die of prostate cancer. This is unfortunate because it is among the most treatable cancers when ...

Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed ...